Amgen, Inc.  

(Public, NASDAQ:AMGN)   Watch this stock  
Find more results for AMGN
163.58
May 22 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range     -
52 week 113.01 - 173.60
Open     -
Vol / Avg. 0.00/3.25M
Mkt cap 124.37B
P/E 22.07
Div/yield 0.79/1.93
EPS 7.41
Shares 760.32M
Beta 0.57
Inst. own 83%
Jul 27, 2015
Q2 2015 Amgen Inc Earnings Release (Estimated) - 4:00PM EDT - Add to calendar
Jun 2, 2015
Amgen Inc Post-ASCO Summary Analyst Call - 2:00PM EDT - Add to calendar
May 14, 2015
Amgen Inc Annual Shareholders Meeting
May 7, 2015
Amgen Inc at Deutsche Bank Health Care Conference - Webcast
Apr 21, 2015
Q1 2015 Amgen Inc Earnings Call - Webcast
Apr 21, 2015
Q1 2015 Amgen Inc Earnings Release
Apr 2, 2015
Amgen at Goldman Sachs Key Debates in Biosimilars
Mar 23, 2015
Amgen Inc Conference Call to Discuss Brodalumab Development Program at American Academy of Dermatology 2015 Annual Meeting - Webcast
Mar 16, 2015
Amgen Inc Conference Call to Discuss Cardiovascular Development Program at American College of Cardiology Scientific Session & Expo - Webcast
Mar 2, 2015
Amgen Inc at Cowen Health Care Conference - Webcast
More events from DailyFinance »    

Key stats and ratios

Q1 (Mar '15) 2014
Net profit margin 32.25% 25.71%
Operating margin 40.17% 30.86%
EBITD margin - 43.16%
Return on average assets 9.44% 7.63%
Return on average equity 24.90% 21.55%
Employees 17,900 -
CDP Score - 64 C

Address

1 Amgen Center Dr
THOUSAND OAKS, CA 91320-1730
United States - Map
+1-805-4471000 (Phone)
+1-805-4471010 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money
Transcripts - SeekingAlpha
About Company - Wikipedia

Description

Amgen Inc. (Amgen) is a global biotechnology company that discovers, develops, manufactures and delivers human therapeutics. It focuses its research and development activities on human therapeutics for in the areas of oncology, hematology, inflammation, bone health, nephrology, cardiovascular and general medicine, which includes neuroscience. The Company’s marketed products include Neulasta, NEUPOGEN, ENBREL, Aranesp, EPOGEN, Sensipar/Mimpara, XGEVA and Prolia. In addition to its marketed products, the Company has various product candidates in mid-to late-stage of development. The Company markets its principal products primarily in the United States in cancer care, inflammation, nephrology and bone disease. As of February 17, 2014, the Company has 16 Phase III programs.

Officers and directors

Robert A. Bradway Chairman of the Board, President, Chief Executive Officer
Age: 52
Bio & Compensation  - Reuters
David W. Meline Executive Vice President, Chief Financial Officer
Age: 57
Bio & Compensation  - Reuters
Madhavan Balachandran Executive Vice President - Operations
Age: 64
Bio & Compensation  - Reuters
Sean E. Harper Executive Vice President - Research and Development
Age: 52
Bio & Compensation  - Reuters
Anthony C. Hooper Executive Vice President - Global Commercial Operations
Age: 60
Bio & Compensation  - Reuters
Brian M. McNamee Executive Vice President - Full Potential Initiatives
Age: 58
Bio & Compensation  - Reuters
Cynthia M. Patton Senior Vice President, Chief Compliance Officer
Age: 53
Bio & Compensation  - Reuters
Stuart A. Tross Senior Vice President - Human Resources
Age: 48
Bio & Compensation  - Reuters
David A. Piacquad Senior Vice President - Business Development
Age: 58
Bio & Compensation  - Reuters
Annette Louise Such Chief Accounting Officer
Age: 46
Bio & Compensation  - Reuters